Krahel, J.A.; Baran, A.; Kamiński, T.W.; Maciaszek, M.; Flisiak, I.
Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J. Clin. Med. 2020, 9, 910.
https://doi.org/10.3390/jcm9040910
AMA Style
Krahel JA, Baran A, Kamiński TW, Maciaszek M, Flisiak I.
Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. Journal of Clinical Medicine. 2020; 9(4):910.
https://doi.org/10.3390/jcm9040910
Chicago/Turabian Style
Krahel, Julita Anna, Anna Baran, Tomasz W. Kamiński, Magdalena Maciaszek, and Iwona Flisiak.
2020. "Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data" Journal of Clinical Medicine 9, no. 4: 910.
https://doi.org/10.3390/jcm9040910
APA Style
Krahel, J. A., Baran, A., Kamiński, T. W., Maciaszek, M., & Flisiak, I.
(2020). Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. Journal of Clinical Medicine, 9(4), 910.
https://doi.org/10.3390/jcm9040910